Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. [electronic resource]
Producer: 19990407Description: 593-600 p. digitalISSN:- 0003-9926
- Adult
- Aged
- Canada
- Cardiovascular Diseases -- economics
- Cerebrovascular Disorders -- economics
- Cost-Benefit Analysis
- Drug Costs
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- economics
- Hypolipidemic Agents -- economics
- Life Expectancy
- Male
- Middle Aged
- Recurrence
- Risk
- Scandinavian and Nordic Countries
- Sensitivity and Specificity
- Simvastatin -- economics
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.